{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:52:09Z","timestamp":1773683529435,"version":"3.50.1"},"reference-count":79,"publisher":"American Diabetes Association","issue":"Supplement_2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:p>Treatment for dyslipidemia in diabetes reduces cardiovascular events. Diabetes is associated with major abnormalities in fatty acid metabolism. The resulting disturbance results in an abnormal lipoprotein cascade from the large chylomicron through to the small HDL particle. This suggests that drugs that alter formation of the chylomicron particle might have a very important role in diabetic dyslipidemia. Achieving normal glycemia will reverse the abnormalities in fatty acid metabolism, but this is difficult, particularly as the disease progresses. Genes that regulate cholesterol absorption and excretion have been described (Niemann Pick C1-like 1 [NPC1-L1] and ATP binding cassette proteins [ABC] G5 and G8). An effective NPC1-L1 inhibitor (ezetimibe) improves the reduction in cholesterol caused by statins. Agonists of ABCG5 and G8 may become important in the treatment of dyslipidemia. Microsomal triglyceride transfer protein (MTP) is responsible for the assembly of the chylomicron and VLDL particles. New MTP inhibitors, acting only on the intestine, are exciting possible treatments. The advisability of sitosterol-enriched foods to lower cholesterol may have to be reassessed for patients with diabetes, since these products may lead to an increase in chylomicron sitosterol in diabetic patients. More successful treatment of diabetic dyslipidemia is essential if we are to reduce the burden of cardiovascular disease so commonly found in diabetes.<\/jats:p>","DOI":"10.2337\/dc08-s260","type":"journal-article","created":{"date-parts":[[2008,1,28]],"date-time":"2008-01-28T22:26:40Z","timestamp":1201559200000},"page":"S241-S248","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":35,"title":["Targets for Intervention in Dyslipidemia in Diabetes"],"prefix":"10.2337","volume":"31","author":[{"given":"Gerald H.","family":"Tomkin","sequence":"first","affiliation":[{"name":"From the Department of Diabetes and Endocrinology, Trinity College Dublin, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031216325700500_R1","doi-asserted-by":"crossref","unstructured":"Tackling the threat to health of diabetes mellitus (Editorial). Lancet\u2008398: 1624, 2006","DOI":"10.1016\/S0140-6736(06)69670-0"},{"key":"2022031216325700500_R2","doi-asserted-by":"crossref","unstructured":"Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med\u2008164:2147\u20132155, 2004","DOI":"10.1001\/archinte.164.19.2147"},{"key":"2022031216325700500_R3","doi-asserted-by":"crossref","unstructured":"Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN: The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med\u2008130:89\u201396, 1999","DOI":"10.7326\/0003-4819-130-2-199901190-00002"},{"key":"2022031216325700500_R4","doi-asserted-by":"crossref","unstructured":"Danaei G, Lawes CMM, Vander Hoorn S, Murray CJL, Ezzati M: Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentrations: comparative risk assessment. Lancet\u2008368:1651\u20131659, 2006","DOI":"10.1016\/S0140-6736(06)69700-6"},{"key":"2022031216325700500_R5","doi-asserted-by":"crossref","unstructured":"Raskin P, Zinman B: The Diabetes Control and Complications Trial Research Group: Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med\u2008329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031216325700500_R6","unstructured":"Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med\u2008353:2643\u20132653, 2005"},{"key":"2022031216325700500_R7","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031216325700500_R8","doi-asserted-by":"crossref","unstructured":"Pyorala K, Pedersen TR, Kjekshus J, Fraergeman O, Olsson AG, Thorgeirsson G: The Scandinavian Simvastatin Survival Study (4S) Group: Cholesterol-lowering with simvastatin improves prognosis of diabetic patients with heart disease. Diabetes Care\u200820:614\u2013620, 1997","DOI":"10.2337\/diacare.20.4.614"},{"key":"2022031216325700500_R9","doi-asserted-by":"crossref","unstructured":"Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia\u200846:760\u2013765, 2003","DOI":"10.1007\/s00125-003-1116-6"},{"key":"2022031216325700500_R10","doi-asserted-by":"crossref","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet\u2008364:685\u2013696, 2004","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"2022031216325700500_R11","doi-asserted-by":"crossref","unstructured":"Fontbonne, Eschweg E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia\u200832:300\u2013304, 1989","DOI":"10.1007\/BF00265546"},{"key":"2022031216325700500_R12","doi-asserted-by":"crossref","unstructured":"Bos G, Dekker JM, Nijpels G, de Vegt FA, Diamant M, Stehouwer CDA, Bouter LM, Heine RJ: A combination of high concentrations of serum triglyceride and non-HDL cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism: The Hoorn Study. Diabetologia\u200846:910\u2013916, 2003","DOI":"10.1007\/s00125-003-1141-5"},{"key":"2022031216325700500_R13","doi-asserted-by":"crossref","unstructured":"Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study: A randomised study. Lancet\u2008357:905\u2013910, 2001","DOI":"10.1016\/S0140-6736(00)04209-4"},{"key":"2022031216325700500_R14","doi-asserted-by":"crossref","unstructured":"The FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet\u2008366:1849\u20131861, 2005","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"2022031216325700500_R15","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med\u200811:534\u2013544, 1994","DOI":"10.1111\/j.1464-5491.1994.tb02032.x"},{"key":"2022031216325700500_R16","doi-asserted-by":"crossref","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R: Heart Protection Study Collaborative Group: MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet\u2008361:2005\u20132016, 2003","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"2022031216325700500_R17","doi-asserted-by":"crossref","unstructured":"Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A, the Israeli Diabetes Research Group: Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med\u2008353:1454\u20131462, 2005","DOI":"10.1056\/NEJMoa050080"},{"key":"2022031216325700500_R18","doi-asserted-by":"crossref","unstructured":"Shafrir E, Raz: I Diabetes: mellitus or lipidus? Diabetologia\u200846:433\u2013440, 2003","DOI":"10.1007\/s00125-003-1052-5"},{"key":"2022031216325700500_R19","doi-asserted-by":"crossref","unstructured":"Shafrir E, Gutman A: Patterns of decrease of free fatty acids during glucose tolerance tests. Diabetes\u200814:77\u201383, 1969","DOI":"10.2337\/diab.14.2.77"},{"key":"2022031216325700500_R20","doi-asserted-by":"crossref","unstructured":"McGarry JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science\u2008258:766\u2013770, 1992","DOI":"10.1126\/science.1439783"},{"key":"2022031216325700500_R21","doi-asserted-by":"crossref","unstructured":"Jouven X, Charles MA, Desnos M, Ducimetiere P: Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation\u2008104:756\u2013761, 2001","DOI":"10.1161\/hc3201.094151"},{"key":"2022031216325700500_R22","doi-asserted-by":"crossref","unstructured":"Kurien VA, Oliver MF: Free fatty acids and cardiac arrhythmias. Lancet\u20081:847, 1970","DOI":"10.1016\/S0140-6736(70)92457-8"},{"key":"2022031216325700500_R23","doi-asserted-by":"crossref","unstructured":"Oliver MF: Sudden cardiac death: the lost fatty acid hypothesis. Q J Med\u200899:701\u2013709, 2006","DOI":"10.1093\/qjmed\/hcl084"},{"key":"2022031216325700500_R24","doi-asserted-by":"crossref","unstructured":"Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A, DIGAMI 2 Investigators: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J\u200826:650\u2013661, 2005","DOI":"10.1093\/eurheartj\/ehi199"},{"key":"2022031216325700500_R25","doi-asserted-by":"crossref","unstructured":"Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med\u2008350:664\u2013671, 2004","DOI":"10.1056\/NEJMoa031314"},{"key":"2022031216325700500_R26","doi-asserted-by":"crossref","unstructured":"Bell JA, Volpi E, Fujita S, Cadenas JG, Rasmussen BB: Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA. Diabetologia\u2008492:144\u2013152, 2006","DOI":"10.1007\/s00125-006-0362-9"},{"key":"2022031216325700500_R27","doi-asserted-by":"crossref","unstructured":"Iozzo P, Turpeinen AK, Takala T, Oikonen V, Bergman J, Gronroos T, Ferrannini E, Nuutila P, Knuuti J: Defective liver disposal of free fatty acids in patients with impaired glucose tolerance. J Clin Endocrinol Metab\u200889:3496\u20133502, 2004","DOI":"10.1210\/jc.2003-031142"},{"key":"2022031216325700500_R28","doi-asserted-by":"crossref","unstructured":"Cnop M, Hannaert JC, Grupping AY, Pipeleers DG: Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology\u2008143:3449\u20133453, 2002","DOI":"10.1210\/en.2002-220273"},{"key":"2022031216325700500_R29","doi-asserted-by":"crossref","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med\u2008333:1301\u20131307, 1995","DOI":"10.1056\/NEJM199511163332001"},{"key":"2022031216325700500_R30","doi-asserted-by":"crossref","unstructured":"Owens D, Maher V, Collins P, Johnson A, Tomkin GH: Cellular cholesterol regulation: a defect in the type 2 (non-insulin-dependent) diabetic patient in poor metabolic control. Diabetologia\u200833:93\u201399, 1990","DOI":"10.1007\/BF00401046"},{"key":"2022031216325700500_R31","doi-asserted-by":"crossref","unstructured":"Bowie A, Owens D, Collins P, Johnson A, Tomkin GH: Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient. Atherosclerosis\u2008102:63\u201367, 1993","DOI":"10.1016\/0021-9150(93)90084-8"},{"key":"2022031216325700500_R32","doi-asserted-by":"crossref","unstructured":"Dimitriadis E, Griffin M, Owens D, Johnson A, Collins P, Tomkin GH: Oxidation of low density lipoprotein in non-insulin dependent diabetes: its relationship to fatty acid composition. Diabetologia\u200838:1300\u20131306, 1995","DOI":"10.1007\/BF00401762"},{"key":"2022031216325700500_R33","doi-asserted-by":"crossref","unstructured":"Dimitriadis EM, Griffin, Owens D, Johnson A, Collins P, Tomkin GH: Lipoprotein composition in NIDDM: the effect of dietary oleic acid on composition and oxidisability and function of low and high density lipoproteins. Diabetologia\u200839:667\u2013676, 1996","DOI":"10.1007\/BF00418538"},{"key":"2022031216325700500_R34","doi-asserted-by":"crossref","unstructured":"Schaefer PG, Teerlink T, Heine RJ: Clinical significance of physiochemical properties in diabetes. Diabetologia\u200848:808\u2013816, 2005","DOI":"10.1007\/s00125-005-1736-0"},{"key":"2022031216325700500_R35","doi-asserted-by":"crossref","unstructured":"Lyon T, Jenkins A: Lipoprotein glycation and its metabolic consequences. Current Opinion In Lipidology\u20088:174\u2013180, 1997","DOI":"10.1097\/00041433-199706000-00008"},{"key":"2022031216325700500_R36","doi-asserted-by":"crossref","unstructured":"Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes\u200848:1\u20139, 2004","DOI":"10.2337\/diabetes.48.1.1"},{"key":"2022031216325700500_R37","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group: MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet\u2008360:23\u201333, 2002","DOI":"10.1016\/S0140-6736(02)09328-5"},{"key":"2022031216325700500_R38","doi-asserted-by":"crossref","unstructured":"Deegan P, Owens D, Collins P, Johnson A, Tomkin GH: The influence of low density lipoprotein composition on its metabolism in non-insulin-dependent diabetes mellitus. Metabolism\u200848:1\u20138, 1999","DOI":"10.1016\/S0026-0495(99)90020-3"},{"key":"2022031216325700500_R39","unstructured":"Salonen JT, Yla-Herttuala S, Yamamoto R, Butler SW, Corpela H, Salonen R, Nyyssonen R, Palinski W, Witztum JL: Autoantibodies against oxidised low density lipoprotein predicting myocardial infarction. Atheroscler Thromb Vasc Biol\u200817:3159\u20133163, 1997"},{"key":"2022031216325700500_R40","doi-asserted-by":"crossref","unstructured":"Griffin M, McInerny D, Collins P, Johnson A, Owens D, Tomkin GH: Autoantibodies to oxidised LDL are related to LDL fatty acid composition in diabetes. Diabet Med\u200814:741\u2013747, 1997","DOI":"10.1002\/(SICI)1096-9136(199709)14:9<741::AID-DIA468>3.0.CO;2-A"},{"key":"2022031216325700500_R41","doi-asserted-by":"crossref","unstructured":"Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, Witztum JL, Xu Q: Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. J Am Coll Cardiol\u200847:2436\u20132443, 2006","DOI":"10.1016\/j.jacc.2006.03.024"},{"key":"2022031216325700500_R42","doi-asserted-by":"crossref","unstructured":"Wilson PWF, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD: Autoantibodies to oxidised LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis\u2008189:364\u2013368, 2006","DOI":"10.1016\/j.atherosclerosis.2005.12.013"},{"key":"2022031216325700500_R43","doi-asserted-by":"crossref","unstructured":"van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, van Eden W, van Berkel TJ, Kuiper J: Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation\u2008114:1968\u20131976, 2006","DOI":"10.1161\/CIRCULATIONAHA.106.615609"},{"key":"2022031216325700500_R44","doi-asserted-by":"crossref","unstructured":"Mastorikou M, Mackness M, Mackness B: Defective metabolism of oxidised phospholipids by HDL from people with type 2 diabetes. Diabetes\u200855:3099\u20133103, 2006","DOI":"10.2337\/db06-0723"},{"key":"2022031216325700500_R45","doi-asserted-by":"crossref","unstructured":"Persegol L, Verges B, Foissac M, Gambert P, Duvillard L: Inability of HDL from diabetic patients to counteract the inhibitory effect if oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia\u200849:1380\u20131386, 2006","DOI":"10.1007\/s00125-006-0244-1"},{"key":"2022031216325700500_R46","doi-asserted-by":"crossref","unstructured":"Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, Heineche JW, Oram JF: Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes\u200854:2198\u20132205, 2005","DOI":"10.2337\/diabetes.54.7.2198"},{"key":"2022031216325700500_R47","doi-asserted-by":"crossref","unstructured":"Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med\u2008318:243\u2013250, 1988","DOI":"10.1056\/NEJM198805193182007"},{"key":"2022031216325700500_R48","doi-asserted-by":"crossref","unstructured":"O'Brien KD, Chait A: Serum amaloid A: the \u201cother\u201d inflammatory protein. Curr Atheroscler Rep\u20088:62\u201368, 2006","DOI":"10.1007\/s11883-006-0066-0"},{"key":"2022031216325700500_R49","doi-asserted-by":"crossref","unstructured":"Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J: Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet\u2008368:1673, 2006","DOI":"10.1016\/S0140-6736(06)69701-8"},{"key":"2022031216325700500_R50","doi-asserted-by":"crossref","unstructured":"Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med\u2008344:1343\u20131350, 2001","DOI":"10.1056\/NEJM200105033441801"},{"key":"2022031216325700500_R51","doi-asserted-by":"crossref","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med\u2008346:393\u2013403, 2002","DOI":"10.1056\/NEJMoa012512"},{"key":"2022031216325700500_R52","doi-asserted-by":"crossref","unstructured":"Xiao C, Giacca A, Carpentier A, Lewis GF: Different effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. Diabetologia\u200849:1371\u20131379, 2006","DOI":"10.1007\/s00125-006-0211-x"},{"key":"2022031216325700500_R53","doi-asserted-by":"crossref","unstructured":"Poynten AM, Gan SK, Kriketos DA, Campbell L, Chisholm DJ: Circulating fatty acid, non-high density lipoprotein cholesterol and insulin infused fat oxidation acutely influence whole body insulin sensitivity in non-diabetic men. J Clin Endocrinol Metab\u200890:1035\u20131040, 2005","DOI":"10.1210\/jc.2004-0943"},{"key":"2022031216325700500_R54","doi-asserted-by":"crossref","unstructured":"Haber EP, Procopio J, Carvalho CR, Carpinelle AR, Newsholme P, Curi R: New insights into fatty acid modulation of pancreatic beta cell function. Int Rev Cytol\u2008248:1\u201341, 2006","DOI":"10.1016\/S0074-7696(06)48001-3"},{"key":"2022031216325700500_R55","doi-asserted-by":"crossref","unstructured":"Newsome P, Keane D, Welters HJ, Morgan NG: Life and death decisions of the pancreatic beta cell: the role of fatty acids. Clin Sci (Lond)\u2008112:27\u201342, 2007","DOI":"10.1042\/CS20060115"},{"key":"2022031216325700500_R56","doi-asserted-by":"crossref","unstructured":"Prentki M, Joly E, El-Assaad W, Roduit R: Malonyl-CoA signalling lipid partitioning and glucolipotoxicity beta cell adaptation and failure in the etiology of diabetes. Diabetes\u200851:S405\u2013S413, 2002","DOI":"10.2337\/diabetes.51.2007.S405"},{"key":"2022031216325700500_R57","doi-asserted-by":"crossref","unstructured":"Fatehi-Hassanabad Z, Chan CB: Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic beta cell function. Nutr Metab (Lond)\u20082:1, 2005","DOI":"10.1186\/1743-7075-2-1"},{"key":"2022031216325700500_R58","unstructured":"DREAM (Diabetes Reduction assessment with Ramipril and Rosiglitazone medication) Trial investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a radomised controlled trial. Lancet\u2008368:1096\u20131105, 2006"},{"key":"2022031216325700500_R59","doi-asserted-by":"crossref","unstructured":"Karpe F, Steiner G, Uffelman K, Olivercrona T, Hamsten A: Postprandial lipoproteins and the progression of coronary atherosclerosis. Atherosclerosis\u2008106:83\u201397, 1994","DOI":"10.1016\/0021-9150(94)90085-X"},{"key":"2022031216325700500_R60","doi-asserted-by":"crossref","unstructured":"Proctor SD, Mamo JC: Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall: evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest\u200828:497\u2013503, 1998","DOI":"10.1046\/j.1365-2362.1998.00317.x"},{"key":"2022031216325700500_R61","doi-asserted-by":"crossref","unstructured":"Gianturco S, Ramprasad M, Song R, Li R, Brown M, Bradley W: Apolipoprotein B48 or its apolipoprotein B100 equivalent mediates binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol\u20088:968\u2013976, 1998","DOI":"10.1161\/01.ATV.18.6.968"},{"key":"2022031216325700500_R62","doi-asserted-by":"crossref","unstructured":"Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH: Improved metabolic control reduces the number of postprandial apolipoprotein B48-containing particles in type 2 diabetes. Atherosclerosis\u2008148:283\u2013291, 2000","DOI":"10.1016\/S0021-9150(99)00275-0"},{"key":"2022031216325700500_R63","doi-asserted-by":"crossref","unstructured":"Taggart C, Gibney J, Owens D, Collins P, Johnson A, Tomkin GH: The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes. Diabet Med\u200814:1051\u20131058, 1997","DOI":"10.1002\/(SICI)1096-9136(199712)14:12<1051::AID-DIA507>3.0.CO;2-Q"},{"key":"2022031216325700500_R64","doi-asserted-by":"crossref","unstructured":"Madigan C, Ryan M, Owens D, Collins P, Tomkin GH: Postprandial lipoprotein particles are deficient in apo E in type 2 diabetes: a cause of postprandial hyperlipidaemia? Ir J Med Sci\u2008174:8\u201321, 2005","DOI":"10.1007\/BF03168513"},{"key":"2022031216325700500_R65","doi-asserted-by":"crossref","unstructured":"Gylling H, Tuominen JA, Koivisto VA, Miettinen TA: Cholesterol metabolism in type 1 diabetes. Diabetes\u200853:2217\u20132222, 2004","DOI":"10.2337\/diabetes.53.9.2217"},{"key":"2022031216325700500_R66","doi-asserted-by":"crossref","unstructured":"Gylling H, Miettinen TA: Cholesterol absorption, synthesis and LDL metabolism in NIDDM. Diabetes Care\u200820:90\u201395, 1997","DOI":"10.2337\/diacare.20.1.90"},{"key":"2022031216325700500_R67","doi-asserted-by":"crossref","unstructured":"O'Meara N, Devery R, Owens D, Collins P, Johnson A, Tomkin GH: Serum lipoproteins and cholesterol metabolism in two hypercholesterolaemic rabbit models. Diabetologia\u200834:139\u2013143, 1991","DOI":"10.1007\/BF00418266"},{"key":"2022031216325700500_R68","doi-asserted-by":"crossref","unstructured":"Lally S, Owens D, Tomkin GH: The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis\u2008193:343\u2013351, 2007","DOI":"10.1016\/j.atherosclerosis.2006.09.031"},{"key":"2022031216325700500_R69","doi-asserted-by":"crossref","unstructured":"Altmann SW, Davis HR Jr, Zhu IJ, Yao X, Hoos LM, Tetzloff F, Iyer Sp, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science\u2008303:1201\u20131204, 2004","DOI":"10.1126\/science.1093131"},{"key":"2022031216325700500_R70","doi-asserted-by":"crossref","unstructured":"Lally S, Tan CY, Owens D, Tomkin GH: mRNA levels of genes involved in dysregulation of postprandial lipoproteins in diabetes: the role of Niemann Pick C1-like 1, ABCG5 and G8 and microsomal triglyceride transfer protein. Diabetologia\u200849:1008\u20131016, 2006","DOI":"10.1007\/s00125-006-0177-8"},{"key":"2022031216325700500_R71","doi-asserted-by":"crossref","unstructured":"Lally S, Owens D, Tomkin GH: Genes that affect cholesterol synthesis, absorption and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism\u200856:430\u2013438, 2007","DOI":"10.1016\/j.metabol.2006.10.028"},{"key":"2022031216325700500_R72","doi-asserted-by":"crossref","unstructured":"Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science\u2008290:1771\u20131775, 2000","DOI":"10.1126\/science.290.5497.1771"},{"key":"2022031216325700500_R73","doi-asserted-by":"crossref","unstructured":"Phillips C, Mullan K, Owens D, Tomkin GH: Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis\u2008187:57\u201364, 2006","DOI":"10.1016\/j.atherosclerosis.2005.08.020"},{"key":"2022031216325700500_R74","doi-asserted-by":"crossref","unstructured":"Lahdenpera S, Syvanne M, Kahri J, Taskinen MR: Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia\u200839:453\u2013461, 1996","DOI":"10.1007\/BF00400677"},{"key":"2022031216325700500_R75","doi-asserted-by":"crossref","unstructured":"Lally S, Owens D, Tomkin GH: Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship to ATP binding cassette proteins G5 and G8 and Niemann Pick C1-like 1 mRNA. Diabetologia\u200850:217\u2013219, 2007","DOI":"10.1007\/s00125-006-0504-0"},{"key":"2022031216325700500_R76","doi-asserted-by":"crossref","unstructured":"Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML: JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord\u20085:30, 2005","DOI":"10.1186\/1471-2261-5-30"},{"key":"2022031216325700500_R77","doi-asserted-by":"crossref","unstructured":"Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, Sawanobori K, Watanabe T, Miyazaki A: A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis\u2008191:290\u2013297, 2007","DOI":"10.1016\/j.atherosclerosis.2006.05.048"},{"key":"2022031216325700500_R78","doi-asserted-by":"crossref","unstructured":"Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH, van Tol A: CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest\u200837:90\u201398, 2007","DOI":"10.1111\/j.1365-2362.2007.01756.x"},{"key":"2022031216325700500_R79","doi-asserted-by":"crossref","unstructured":"Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM: Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol\u200826:1572\u20131578, 2006","DOI":"10.1161\/01.ATV.0000225700.43836.ae"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/Supplement_2\/S241\/469461\/zdc1020800s241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/31\/Supplement_2\/S241\/469461\/zdc1020800s241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:02:43Z","timestamp":1647104563000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/31\/Supplement_2\/S241\/24768\/Targets-for-Intervention-in-Dyslipidemia-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":79,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc08-s260","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}